Marlio Charles Mosseri bought $957k of NVCT
owner at Nuvectis Pharma, Inc.. 154,770 shares at an average of $6.18, traded Oct 23, 2025, filed Oct 29, 2025.
Score components
- +12Role10% owner
- +24Trade size$957k at market
- +3Relative to holdingsHoldings up 5%
- +8Price context45% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.8%, 3m +23.6%, 6m +25.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-103522, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 23, 2025 | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +46,900 | $6.06 | $284k | 3,028,706 | Oct 29, 2025 |
| Oct 24, 2025 | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +35,034 | $6.15 | $215k | 3,063,740 | Oct 29, 2025 |
| Oct 27, 2025 | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +72,836 | $6.28 | $457k | 3,136,576 | Oct 29, 2025 |
Related signals
Other insiders at Nuvectis Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 59Moderate | Nuvectis Pharma, Inc. | Ron Bentsur Chairman & CEO | $250k 12,500 shares | +0% | |
| 47Moderate | Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $916k 50,000 shares | +2% | |
| 48Moderate | Nuvectis Pharma, Inc. | Ron Bentsur Chairman & CEO | $29k 5,000 shares | +0% | |
| 49Moderate | Nuvectis Pharma, Inc. | Matthew L. Kaplan director | $64k 11,000 shares | +10% | |
| 49Moderate | Nuvectis Pharma, Inc. | Juan Sanchez director | $75k 13,000 shares | +20% | |
| 17Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $45k 5,603 shares | +0% | |
| 29Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $270k 33,442 shares | +1% | |
| 22Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $172k 21,167 shares | +1% | |
| 24Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $247k 27,662 shares | +1% | |
| 19Weak | NVCTbuy Nuvectis Pharma, Inc. | Marlio Charles Mosseri owner | $236k 27,411 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.